Papers
1.Nie S; Li B; Wang M; Chen Z; Ren J; Li Z; Xu X; Qian Z; Xie Z; Han J; Zhang Z; Zhang Z; Zhu Y; Chen Z; Yang X; Ye K. Sox6 and ALDH1A1 Truncation by Asparagine Endopeptidase Defines Selective Neuronal Vulnerability in Parkinson's Disease. Adv Sci (Weinh). 2024 Nov 21:e2409477. doi: 10.1002/advs.202409477. Online ahead of print. PMID: 39573918
2.Xiang J; Tang J; Kang F; Ye J; Cui Y; Zhang Z; Wang J; Wu S; Ye K. Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson's and Alzheimer's disease co-pathology and behavior impairments. Neuron. 2024 Aug 30:S0896-6273(24)00576-2. doi: 10.1016/j.neuron.2024.08.003. Online ahead of print.PMID: 39241780
3.Xiong J; Kang SS; Wang M; Wang Z; Xia Y; Liao J; Liu X; Yu SP; Zhang Z; Ryu V; Yuen T; Zaidi M; Ye K. FSH and ApoE4 contribute to Alzheimer's disease-like pathogenesis via C/EBPβ/δ-secretase in female mice. Nat Commun. 2023 Oct 18;14(1):6577. doi: 10.1038/s41467-023-42282-7.PMID: 37852961
4.Xiang J; Tao Y; Xia Y; Luo S; Zhao Q; Li B; Zhang X; Sun Y; Xia W; Zhang M; Kang SS; Ahn EH; Liu X; Xie F; Guan Y; Yang JJ; Bu L; Wu S; Wang X; Cao X; Liu C; Zhang Z; Li D; Ye K. Development of an α-synuclein positron emission tomography tracer for imaging synucleinopathies. Cell. 2023 186 (16) 3350-3367. doi: 10.1016/j.cell.2023.06.004.
5.Xia Y; Xiao Y; Wang ZH; Liu X; Alam AM; Haran JP; McCormick BA; Shu X; Wang X; Ye K. Bacteroides Fragilis in the gut microbiomes of Alzheimer's disease activates microglia and triggers pathogenesis in neuronal C/EBPβ transgenic mice. Nat Commun. 2023 Sep 6;14(1):5471. doi: 10.1038/s41467-023-41283-w.PMID: 37673907
6.Xiong J; Liao J; Liu X; Zhang Z; Adams J; Pacifici R; Ye K. A TrkB agonist prodrug prevents bone loss via inhibiting asparagine endopeptidase and increasing osteoprotegerin. Nat Commun. 2022 Aug 16;13(1):4820. doi: 10.1038/s41467-022-32435-5.
7.Chen G; Ahn EH; Kang SS; Xia Y; Liu X; Zhang Z; Ye K. UNC5C Receptor Proteolytic Cleavage by Active AEP Promotes Dopaminergic Neuronal Degeneration in Parkinson's Disease. Adv Sci (Weinh). 2022 Mar;9(7):e2103396. doi: 10.1002/advs.202103396. Epub 2022 Jan 12.
8.Kang SS; Meng L; Zhang X; Wu Z; Mancieri A; Xie B; Liu X; Weinshenker D; Peng J; Zhang Z; Ye K. Tau modification by the norepinephrine metabolite DOPEGAL stimulates its pathology and propagation. Nat Struct Mol Biol. 2022 Mar 24. 29(4):292-305.doi: 10.1038/s41594-022-00745-3.
9.Chen C; Liao J; Xia Y; Liu X; Jones R; Haran J; McCormick B; Sampson TR; Alam A; Ye K. Gut microbiota regulate Alzheimer's disease pathologies and cognitive disorders via PUFA-associated neuroinflammation. Gut. 2022 Jan 11:gutjnl-2021-326269. doi: 10.1136/gutjnl-2021-326269.
10.Xiong J; Kang SS; Wang Z; Liu X; Kuo TC; Korkmaz F; Padilla A; Miyashita S; Chan P; Zhang Z; Katsel P; Burgess J; Gumerova A; Ievleva K; Sant D; Yu SP; Muradova V; Frolinger T; Lizneva D; Iqbal J; Goosens KA; Gera S; Rosen CJ; Haroutunian V; Ryu V; Yuen T; Zaidi M; Ye K. FSH blockade improves cognition in mice with Alzheimer's disease. Nature. 2022 Mar. 603(7901):470-476. doi: 10.1038/s41586-022-04463-0.
11.Xia Y; Qadota H; Wang ZH; Liu P; Liu X; Ye KX; Matheny CJ; Berglund K; Yu SP; Drake D; Bennett DA; Wang XC; Yankner BA; Benian GM; Ye K. Neuronal C/EBPβ/AEP pathway shortens life span via selective GABAnergic neuronal degeneration by FOXO repression. Sci Adv. 2022 Apr;8(13):eabj8658. doi: 10.1126/sciadv.abj8658. Epub 2022 Mar 30.
12.Jasmin M; Ahn EH; Voutilainen MH; Fombonne J; Guix C; Viljakainen T; Kang SS; Yu LY; Saarma M; Mehlen P; Ye K. Netrin-1 and its receptor DCC modulate survival and death of dopamine neurons and Parkinson's disease features. EMBO J. 2021, e105537, doi:10.15252/embj.2020105537.
Patents
1.Noscapine and Noscapine Derivatives, Useful as Anticancer Agents,USA,US6376516B1
2.Delivery Systems and Methods for Noscapine and Noscapine Derivatives,Useful as Anticancer Agents,USA,US6673814B2
3.Neurotrophic Activity of Deoxygedunin,USA,US8203009B2
4.Treating various disorders using TrkB agonists,USA,US8609870B2
5.Methods of managing blood sugar levels and compositions related thereto,USA,US9040713B2
6.Catecholamine Derivatives for Obesity and Neurological Disorders,USA,US9266817B2
7.TrkB Agonists and Methods of Use,USA,US9504674B2
8.Treatment of neurodegenerative diseases with asparagjne (AEP) inhibitors and compositions related thereto,USA,US20170029388A1
9.Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof,USA,US9895344B2
10.7,8-Dihydoxyflavone and 7,8-substituted Flavone Derivatives, Compositions, and Methods Related Thereto,USA,US9975868B2
11.Heterocyclic Flavone Derivatives, Compositions, And Methods related thereto,USA,US10596145B2
12.Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto,USA,US10759803B2
13.Asparagine endopeptidase (AEP) inhibitors, compositions, and uses related thereto,WOPI,WO2020242933A1
14.Heterocyclic flavone derivatives, compositions, and methods related thereto,USA,US20210292335A1
15.Inhibitors of glutathione s-transferases (gsts) and nad(p)h:quinone oxidoreductase 1 (nqo1), pharmaceutical compositions, and uses in managing cancer,WIPO,WO2021150756A1
16.Styrylbenzothiazole derivatives and uses in imaging,WIPO,WO2019222454 A1
17.Styrylbenzothiazole derivatives and uses in imaging,USA,US11844846B2
18.Methods of using substituted flavones for treating bone disorders,WIPO,WO2023288069A1
19.compositions and methods for treating neurodegenerative diseases by inhibiting FSH,WIPO,WO2023004044A2
20.Methods of managing blood sugar levels and compositions related thereto,WIPO,WO2012047628A2